APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PARP (Poly ADP-Ribose Polymerase) Inhibitor

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

Selected research

Market Structure

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174022500321 December 2025182 pages

Choose your research edition.

Industry ResearchPARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

Read the full market overview

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.

North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.

In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.

This report provides an overview of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PARP (Poly ADP-Ribose Polymerase) Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PARP (Poly ADP-Ribose Polymerase) Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PARP (Poly ADP-Ribose Polymerase) Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Company

AstraZeneca

Tesaro

Merck & Co

Clovis Oncology

Pfizer

GSK

Zai Lab

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type

Lynparza

Zejula

Rubraca

Talzenna

Other

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application

Ovarian Cancer

Breast Cancer

Other

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PARP (Poly ADP-Ribose Polymerase) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PARP (Poly ADP-Ribose Polymerase) Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PARP (Poly ADP-Ribose Polymerase) Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends Table 2. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers Table 3. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges Table 4. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints Table 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (k units) & (2021-2026) Table 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers Table 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers, Product Type & Application Table 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lynparza Table 17. Major Manufacturers of Zejula Table 18. Major Manufacturers of Rubraca Table 19. Major Manufacturers of Talzenna Table 20. Major Manufacturers of Other Table 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2026) & (k units) Table 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2027-2032) & (k units) Table 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021-2026) Table 25. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2027-2032) Table 26. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2026) & (k units) Table 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2027-2032) & (k units) Table 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021-2026) Table 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Ovarian Cancer Table 32. Major Manufacturers of Breast Cancer Table 33. Major Manufacturers of Other Table 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2026) & (k units) Table 36. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2027-2032) & (k units) Table 37. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021-2026) Table 38. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2027-2032) Table 39. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2026) & (k units) Table 41. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2027-2032) & (k units) Table 42. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021-2026) Table 43. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2027-2032) Table 44. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021-2026) & (k units) Table 46. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2021-2026) Table 47. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 49. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 51. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 52. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 54. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 61. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 63. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 64. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2021-2026) Table 65. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2027-2032) Table 66. AstraZeneca Company Information Table 67. AstraZeneca Business Overview Table 68. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 70. AstraZeneca Recent Development Table 71. Tesaro Company Information Table 72. Tesaro Business Overview Table 73. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 75. Tesaro Recent Development Table 76. Merck & Co Company Information Table 77. Merck & Co Business Overview Table 78. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 80. Merck & Co Recent Development Table 81. Clovis Oncology Company Information Table 82. Clovis Oncology Business Overview Table 83. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 85. Clovis Oncology Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 90. Pfizer Recent Development Table 91. GSK Company Information Table 92. GSK Business Overview Table 93. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 95. GSK Recent Development Table 96. Zai Lab Company Information Table 97. Zai Lab Business Overview Table 98. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 100. Zai Lab Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List Table 104. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Image Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2021-2032) & (k units) Figure 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lynparza Image Figure 9. Zejula Image Figure 10. Rubraca Image Figure 11. Talzenna Image Figure 12. Other Image Figure 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021-2032) Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021-2032) Figure 19. Ovarian Cancer Image Figure 20. Breast Cancer Image Figure 21. Other Image Figure 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021-2032) Figure 25. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021-2032) Figure 28. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021-2032) Figure 30. U.S. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021-2032) Figure 35. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 36. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021-2032) Figure 42. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 46. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021-2032) Figure 50. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Figure 61. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Figure 63. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Figure 69. Manufacturing Cost Structure Figure 70. PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Lynparza
  • Zejula
  • Rubraca
  • Talzenna
  • Other
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • AstraZeneca
  • Tesaro
  • Merck & Co
  • Clovis Oncology
  • Pfizer
  • GSK
  • Zai Lab

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics
  1. 2.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
  2. 2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers
  3. 2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges
  4. 2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints
3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Manufacturers
  1. 3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PARP (Poly ADP-Ribose Polymerase) Inhibitor Tier 1, Tier 2, and Tier 3
4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Type
  1. 4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type Introduction
  2. 4.1.1 Lynparza
  3. 4.1.2 Zejula
  4. 4.1.3 Rubraca
  5. 4.1.4 Talzenna
  6. 4.1.5 Other
  7. 4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
  8. 4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032)
  10. 4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021-2032)
  11. 4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type
  12. 4.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2032)
  14. 4.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021-2032)
5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Application
  1. 5.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Application Introduction
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Other
  5. 5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
  6. 5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032)
  8. 5.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021-2032)
  9. 5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application
  10. 5.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2032)
  12. 5.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021-2032)
6 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region
  1. 6.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region
  1. 7.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region
  2. 7.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Tesaro
  8. 8.2.1 Tesaro Company Information
  9. 8.2.2 Tesaro Business Overview
  10. 8.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  12. 8.2.5 Tesaro Recent Developments
  13. 8.3 Merck & Co
  14. 8.3.1 Merck & Co Company Information
  15. 8.3.2 Merck & Co Business Overview
  16. 8.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  18. 8.3.5 Merck & Co Recent Developments
  19. 8.4 Clovis Oncology
  20. 8.4.1 Clovis Oncology Company Information
  21. 8.4.2 Clovis Oncology Business Overview
  22. 8.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  24. 8.4.5 Clovis Oncology Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 Zai Lab
  38. 8.7.1 Zai Lab Company Information
  39. 8.7.2 Zai Lab Business Overview
  40. 8.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  42. 8.7.5 Zai Lab Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Analysis
  2. 9.1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process
  6. 9.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
  9. 9.2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst